Workflow
河北石家庄以创新为引领打造生物医药产业高地

Group 1 - The core viewpoint of the news is the strategic R&D cooperation agreement between CSPC Pharmaceutical Group and AstraZeneca, with a total contract value of $5.33 billion for the discovery and development of new oral small molecule drug candidates using AI technology [1] - CSPC has previously licensed 11 products overseas, with a total contract value exceeding $7.3 billion, indicating a strong track record in international collaborations [1] - CSPC currently has over 200 innovative drug projects under research and ranks 19th in the global pharmaceutical R&D pipeline scale as of 2025 [1] Group 2 - Shijiazhuang City is actively promoting high-quality development in the biopharmaceutical industry, implementing comprehensive support measures across the entire lifecycle of the industry [1] - The city has revised and issued measures to support breakthroughs in the new generation of electronic information and biopharmaceutical industries, providing a total of 290 million yuan in rewards to biopharmaceutical companies since 2021, including 79.25 million yuan to CSPC [1] - Shijiazhuang City is committed to optimizing the business environment and has implemented targeted support for leading enterprises, addressing over ten operational issues for CSPC this year [1][2]